MMV Request for Proposals: 19th Call for Drug Discovery

Medicine for Malaria Venture (MMV) with the mission to reduce the burden of malaria in disease-endemic countries by discovering, developing and delivering new, effective and affordable antimalarial drugs. MMV welcomes proposals in the following areas of the drug discovery process:

1. Drug discovery projects:

• Compounds having activity against Plasmodium falciparum blood stages and ideally an inability to select resistant mutants in vitro (TCP1): novel chemical series with EC₅₀<500nM.
• Compounds having activity against Plasmodium falciparum liver stages for use in prophylaxis (TCP4): novel chemical series with EC₅₀<500nM.
• Compounds addressing the key priorities of the malaria eradication agenda (TCP3 and TCP5): novel families of molecules in the hit-to-lead or lead optimization stages, without G6PD deficiency liabilities.

2. Compounds for target identification: MMV also welcomes requests for support to investigate the mechanism of action of compounds:

• Plasmodium whole cell EC₅₀ <1uM and the chemical structure can be shared
• At least 10mgs of compound can be provided to the consortium

3. African proposals: finally, MMV welcomes proposals only from endemic region African scientists focused in the following priority areas:

• Compounds with confirmed activity on any antimalarial life-cycle stage
• Assay development and screening

Read more here. 

Proposals deadline March 26, 2021.